Company news

VYNE Therapeutics Inc. news in 2025

VYNE Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.

View company

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

December 17, 2025

VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

November 6, 2025

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

August 14, 2025

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

July 30, 2025

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

July 2, 2025

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

May 8, 2025

VYNE Therapeutics Provides Update on VYN202 Program

April 25, 2025

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

March 20, 2025

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

March 6, 2025

VYNE Therapeutics to Participate in March Investor Conferences

February 20, 2025

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

February 19, 2025

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

January 5, 2025

Decks in 2025